ArticleAnnals of gastroenterology
Hybrid therapy as first-line regimen for
Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 17 citations in OpenAlex.
- Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.PloS one · 2020Trial
- Equivalence Trial of the Non-Bismuth 10-Day Concomitant and 14-Day Hybrid Therapies forAntibiotics (Basel, Switzerland) · 2024Article
- The status and progress of first-line treatment againstTherapeutic advances in gastroenterology · 2021Review
- Molecular Detection of Antibiotic-Resistant Helicobacter pylori.Methods in molecular biology (Clifton, N.J.) · 2021Article
- BestAntibiotics (Basel, Switzerland) · 2020Review
- Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.Digestive diseases and sciences · 2020Review
- Assessment of first-line eradication treatment in Greece: data from the European Registry onAnnals of gastroenterologyArticle
- Hellenic consensus onAnnals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHybrid therapy is a promising first-line regimen for
methodsThis was a prospective study that included 155 treatment-naïve patients diagnosed with
resultsThe eradication rates were 85.8% (133/155; 95% confidence interval [CI] 79.4-90.5%) by intention-to-treat and 90.2% (129/143; 95%CI 84.1-94.2%) by per-protocol analysis in a setting of high antibiotic resistance (clarithromycin 25.9%, metronidazole 31.1%, dual resistance 8.9%). Adverse events occurred in 29.7% and 1.3% discontinued treatment because of adverse events. Adherence >90% was achieved in 96.6%. The eradication rate in patients with dual clarithromycin/metronidazole resistance (50%) was markedly lower compared to those with single clarithromycin resistance (91.4%), single metronidazole resistance (90.5%) or dual susceptibility (97.8%). Dual resistance was the only factor to correlate with the failure of hybrid therapy (odds ratio 14.4, 95%CI 3.8-54.9, P=0.0003).
conclusionsHybrid therapy is an effective and safe first-line regimen in populations with relatively high rates of antibiotic resistance. However, dual clarithromycin/metronidazole resistance may significantly compromise its efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.